Top segments and regional performance

Last year, the company generated ‪2.79 M‬ USD, the most of which — ‪2.79 M‬ USD — came from its top-performing segment, Oncology Therapeutics, compared to ‪226.00 K‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪2.79 M‬ USD last year, with ‪226.00 K‬ USD the year before.